Track Alloy Therapeutics
— get Health deals in free daily digest
Overview
Alloy Therapeutics has raised $40 million in a Series E round, valuing the Boston-based biotech company at $1 billion. The funding will enhance its tech-enabled drug development platform, which integrates AI with laboratory and clinical capabilities. Key investors include 8VC and JIC Venture Growth Investments, alongside returning firms like Mubadala Capital and Founders Fund. Alloy supports over 100 licensed therapeutic programs, with 22 in clinical development, and aims to streamline drug development for virtual biotech firms.
Products
Loading...
Recent Deals
Investors: 8VC,JIC Venture Growth Investments,Mubadala Capital,Founders Fund
Alloy Therapeutics has raised $40 million in a Series E round, valuing the Boston-based biotech company at $1 billion. The funding will enhance its tech-enabled drug development platform, which integrates AI with laboratory and clinical capabilities. Key investors include 8VC and JIC Venture Growth Investments, alongside returning firms like Mubadala Capital and Founders Fund. Alloy supports over 100 licensed therapeutic programs, with 22 in clinical development, and aims to streamline drug development for virtual biotech firms.